DM-005, a bispecific ADC with robust efficacy in preclinical models

Nov. 10, 2023

Researchers from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. and Doma Biopharmaceutical (Suzhou) Co. Ltd. reported the discovery and preclinical data of DM-005, a novel fully human EGFR × MET bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.

BioWorld Science Conferences Society for Immunotherapy of Cancer Cancer Antibody-drug conjugate Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for Nov. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for November 27, 2024.

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

AI-generated illustration of heart and metabolic impact

Bridgebio, with FDA approval, faces Pfizer in ATTR

BioWorld

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...

‘Evo’ AI can design complete genomes

BioWorld Science

The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

Upgrade your daily dose of biopharma and medtech news

DM-005, a bispecific ADC with robust efficacy in preclinical models